UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
AND RULE 13A-17 OR 15D-17 THEREUNDER
The Liposome Company, Inc.
(Exact name of issuer as specified in charter)
One Research Way, Princeton Forrestal Center, Princeton, NJ 08540
(Address of principal Executive offices)
Issuer's telephone number, including area code (609) 452-7060
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number of shares
outstanding:
1.Title of Security Depositary Shares, each representing 1/10th of a share of
the Series A Cumulative Convertible Exchangeable Preferred Stock of The
Liposome Company, Inc.
2. Number of shares
outstanding before the change 2,733,500
3. Number of shares
outstanding after the change 1,364,656
4. Effective date of
change March 25, 1996 (effective date of redemption)
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.) Conversion and
redemption of Preferred Stock
Give brief description of transaction 1,359,984 Depositary Shares were
surrendered for conversion into Common Stock,
and 8,860 Depositary Shares were surrendered for redemption.
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
2. Name after change
3. Effective date of
charter amendment changing name
4. Date of shareholder
approval of change, if required
Date April 2, 1996
(Officer's signature & title)
Vice President, General Counsel and Secretary
